Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveEnrolling Location: Australia

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052) , protocol number ACTRN12605000156684

    Fungal exposure and fungal-specific IgE in subjects with cystic fibrosis (Australian Cystic Fibrosis Research Trust 2004/052)

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIActive, not recruiting Location: Australia

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis. , protocol number ACTRN12605000426684

    Prevalence and predictors of malnutrition and decreased bone density in cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Nutritional-GIRecruiting Location: Australia

    Gastric emptying and malnutrition in adults with cystic fibrosis. , protocol number ACTRN12605000427673

    Gastric emptying and malnutrition in adults with cystic fibrosis.

    • Age:

      >18 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF). , protocol number ACTRN12605000348651

    Effect of Positive Expiratory Pressure (PEP) on the duration of the exacerbation-free period in people with cystic fibrosis (CF).

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 within 15% of their best recorded value as an outpatient for the preceding six months

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: Australia

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease. , protocol number ACTRN12605000780651

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease.

    • Age:

      >17 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: Australia

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis. , protocol number ACTRN12606000053527

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis.

    • Age:

      No limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      >40% pred.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Australia - NSW, QLD, SA, VIC, WA

    Prevention of Bronchiectasis in Infants with Cystic Fibrosis , protocol number NCT01270074

    The general aim of this project is to conduct a randomised, double-blind, placebo-controlled clinical trial of azithromycin to determine whether treatment from infancy is safe and will prevent the onset of bronchiectasis. One hundred and thirty infants will be recruited from CF clinics in Australia and New Zealand and treated from 3 months to three years of age. The outcome will be the proportion with radiologically-defined bronchiectasis at 3 years of age. Safety and mechanistic evaluations will also be undertaken.

    • Age:

      Maximum 6 months

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Australia - NSW, QLD, SA

    Insulin Deficiency, Early Action , protocol number NCT01100892

    Cystic fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. Te CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.

    • Age:

      5 - 19 Years

    • Mutation(s):

      CFID1 or CFID2

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis? , protocol number ACTRN12605000728639

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis?

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    Evaluation of CF patient perception of symptom improvement following inhaled antibiotic treatment. , protocol number ACTRN12605000602628

    Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).

    • Age:

      6 years - no stated upper limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 11-20 (of 178)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|